Sorted By:


New Spanish-language resources added to ABCs En Español

PhRMA  |  Blog Post

Learn more about how we can better engage and empower patients, and visit for other English-language resources.ñol

Medicines in Development for Parkinson's Disease 2014 Report

PhRMA  |  Report

America’s biopharmaceutical research companies are currently developing 37 medicines to help the estimated 1.5 million Americans living with Parkinson’s Disease, a motor system disorder resulting from the loss of dopamine-producing brain cells. All of the medicines are either in clinical trials o...

Medicines in Development for Mental Illnesses 2017 Report

PhRMA  |  Report

Biopharmaceutical research companies are developing more than 140 medicines for mental illnesses. Mental illnesses exact a heavy human and economic toll in the United States. The National Institute of Mental Health (NIMH) estimates that nearly 18 percent of American adults and 20 percent of child...

Medicare Monday: What you need to know about the latest Medicare Trustees report

PhRMA  |  Blog Post

For 2016, the Trustees report found that Medicare Part D beneficiaries increased generic drug use to 87 percent of all prescriptions – up from 86 percent in 2015 and 85 percent in 2014.

Charles River Associates Releases Updated HTA Comparison Report

PhRMA  |  Press Release

The report’s findings underscore the importance of patient-centered, evidence-informed and holistic approaches to effectively and efficiently increase equitable access to quality healthcare services.

Medicines in Development for Biologics 2013 Report

PhRMA  |  Report

This report lists biologics in human clinical trials or under review by the U.S.

Medicines in Development for Cancer 2015 Report

PhRMA  |  Report

In recent decades, tremendous – almost previously unthinkable – progress has been made in the fight against cancer. Advances in molecular and genomic research have revealed underlying complexities and provided insights into cancer, which we now know is actually more than 200 unique diseases. Cont...

4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report

PhRMA  |  Blog Post

Here are four things you should know about the latest QuintilesIMS report: Prices for existing brand-name medicines declined by an average of 2.5 percent annually over the last six years, primarily due to patent expirations and generic competition.

PhRMA Launches New Spanish-Language Health Care Resources

Access Better Coverage  |  From Our Network

For more resources, visit

New report and event examine the new era of vaccines

PhRMA  |  Blog Post

Our 2017 Medicines in Development: Vaccines update, released today, highlights the more than 260 vaccines in development to treat and prevent disease.

PhRMA Statement on Consumer Reports Study

PhRMA  |  Press Release

(March 18, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding the Best Drugs for Less report by Consumers Union: "PhRMA supports efforts to make sure patients and providers have high-quality information to guide their treatment and health care decisions.

PhRMA launches biologics and biosimilars online resources

PhRMA  |  Blog Post

As the regulatory environment surrounding these medicines continues to evolve, PhRMA will develop and offer additional resources on the page that provide key facts on these milestones.

Medicines in Development for Osteoporosis 2016 Report

PhRMA  |  Report

Osteoporosis causes loss of bone mass and deterioration of bone structure, leading to fragile and easily fractured bones. Although osteoporosis mainly affects women, men are also at risk for the disease. In fact, half of women and a quarter of men over the age of 50 will break a bone due to osteo...

Medicines in Development for COPD 2012 Report

PhRMA  |  Report

“The promising new therapies highlighted in this report illustrate how emerging scientific approaches, to treating respiratory diseases such as COPD, offer great hope to improve and save the lives of future patients.”

Tackling Impediments to Trade

PhRMA  |  Report

The vast majority of the world’s medical innovation occurs in the United States because of a reliable patent system where risk is rewarded, innovators are protected, and a predictable flow of resources fuels continuous research and development.

PhRMA Statement on Misleading Reports About Price Growth

PhRMA  |  Press Release

News and World Reportshows pharmaceutical companies lagging far behind other sectors when it comes to median stock performance, rising by only 2.5% over the past 12 months compared to 27% for the overall S&P 500 and 34% for hospitals and health insurers.

PhRMA Statement on Supporting Safe Disposal Resources

PhRMA  |  Press Release

Washington, D.C. (October 31, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President of Communications Matthew Bennett issued the following statement today:    “Now more than ever, it’s important to remind those who have unused an...

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

PhRMA  |  Blog Post

We view the report as a potential basis for engaging trading partners to more effectively address negative practices and regain a level-playing field for American companies – particularly those that rely heavily on IP protections like companies in the innovative biopharmaceutical industry.

Medicines in Development for Arthritis 2014 Report

PhRMA  |  Report

Approximately 15 million adults report that they are unable to perform some common activities due to the pain; 10 for osteoarthritis, the most com-mon form of arthritis, which affects nearly 27 million Americans; and 7 for psoriatic arthritis, an in?

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines

PhRMA  |  Blog Post

Learn more about Part B at and find the report here.

New Report Shows 74 Percent of Medicines in Development have Potential to be First-in-Class Treatments

PhRMA  |  Press Release

To view the full Pipeline report: To view the executive summary:   About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives.

Clinical Trials

PhRMA  |  From PhRMA

Biopharmaceutical research and clinical trials are taking place across the U.S. every day. Explore the interactive map below and select a state to access data on biopharmaceutical jobs, the industry's overall economic impact, clinical trial activity, and more. ...

Medicines in Development for Alzheimer's Disease 2017 Report

PhRMA  |  Report

America’s biopharmaceutical research companies are investigating or developing 85 medicines to help the more than 5 million patients in the United States who are living with Alzheimer’s disease. The medicines in development are all in either clinical trials or under review by the Food and Drug Ad...

ICYMI: Report highlights overall decrease in cancer death rates

PhRMA  |  Blog Post

When comparing data from 1975 to 1977 and 2006 to 2012, the report found the five-year survival rates for some distant-stage types of cancer increased significantly.

Medicines in Development for Neurological Disorders 2015 Report

PhRMA  |  Report

Learn more in the Medicines in Development report

You have reviewed the first 50 results out of 1012. Each page contains 25 results. You're on page 2.

prev 1 2 3 4 5 6 next